Testosterone and its Preventive Role in Men’s Health: Prostate Cancer

We investigated the role of testosterone therapy (TTH) in prostate safety and cancer progression.A cohort of 553 patients, 42 treated and 162 untreated hypogonadal men, and 349 eugonadal men were included.Pathological analysis of prostate biopsies examining the incidence and severity of Prostate Cancer (PCa) revealed that: 16.7% of treated hypogonadal men had a positive biopsy, a Gleason score of 6 in 71.4% and >6 in 28.6% of men, a predominant score of 3 and tumor staging of II in 85.7% men; 51.9% of untreated hypogonadal men had a positive biopsy, a Gleason score of 6 in 40.5% and >6 in 59.5% men, a predominant score of 3 (77.4%)and tumor staging of II (41.7%) or III (40.5%); 37.8% of eugonadal men had a positive biopsy, a Gleason score of 6 in 42.4% and >6 in 57.6% of men, a predominant score of 3 (82.6%)and tumor staging of II (44.7%) or III (47.7%).The incidence of positive prostate biopsies was lowest in hypogonadal men receiving TTH, with significantly lower severity of PCa in terms of staging and grading in the same group.These results suggest that TTH might have a protective effect against high-grade PCa.